BioWorld

May 3, 2002

AVI Starting Avicine Phase III To Speed Approval Timeline

AVI BioPharma Inc. changed the course for its lead anticancer product, the vaccine Avicine, in an effort to shorten the route toward a possible FDA approval. (BioWorld Today) Read More

Syrrx Enters Deal To Provide Roche With Protein Structures

Demyelination Is Mycobacterium leprae’s Nerve Killer In Infectious And Neurodegenerative Diseases

Nyxis Getting Ready To Move Glyxins Family Into The Clinic

Other News To Note

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...